November 18, 2025 a 07:43 pm
LLY: Fundamental Ratio Analysis - Eli Lilly and Company
Eli Lilly and Company, a major player in the pharmaceutical industry, showcases a diverse product range addressing numerous medical needs worldwide. With a steady growth trajectory and collaborations propelling innovation, the LLY stock presents an investment opportunity worth considering for those interested in the healthcare sector.
Fundamental Rating
Eli Lilly and Company's fundamentals are stable, with particular strengths in return metrics. The overall rating is categorized as 'B', indicating moderate growth potential with low risks.
| Category | Score | Visual |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical Rating
Historically, Eli Lilly and Company's financial metrics have remained stable, demonstrating consistent performance.
| Date | Overall Score | DCF | ROE | ROA | Debt to Equity | Price to Earnings | Price to Book |
|---|---|---|---|---|---|---|---|
| 2025-11-18 | 3 | 4 | 5 | 5 | 1 | 1 | 1 |
| Prior Date | 0 | 4 | 5 | 5 | 1 | 1 | 1 |
Analyst Price Targets
The consensus price target reflects a strong belief in the stock's potential, with highs of $985 and a median target of $889.
| High | Low | Median | Consensus |
|---|---|---|---|
| 985 | 700 | 889 | 854.67 |
Analyst Sentiment
Analysts are bullish on the stock, with a majority of buy recommendations supporting continued confidence in growth and stability.
| Recommendation | Count | Visual |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 31 | |
| Hold | 11 | |
| Sell | 2 | |
| Strong Sell | 0 |
Conclusion
Eli Lilly and Company remains a formidable force in the pharmaceutical industry, demonstrating robust financials and strong growth potential. Investor sentiment is positive, reflected in favorable analyst ratings and bullish price targets. However, monitoring debt levels and valuation metrics is advised to ensure sustained performance. In conclusion, Eli Lilly offers a balanced investment opportunity with promising future prospects tempered by the general market and sector-specific risks.